^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

NECTIN4 expression

i
Other names: NECTIN4, Nectin Cell Adhesion Molecule 4, Nectin-4, LNIR, PRR4, Poliovirus Receptor-Related Protein 4, Poliovirus Receptor-Related 4, Ig Superfamily Receptor LNIR, PVRL4, Nectin 4, EDSS1
Entrez ID:
Related biomarkers:
11d
TROP-2, NECTIN-4 and predictive biomarkers in sarcomatoid and rhabdoid bladder urothelial carcinoma. (PubMed, Pathologica)
Different combinations of other positive biomarkers may help the choice of medical therapies. Overall, these findings have important clinical implications for targeted therapy for BUC.
Journal • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • FGFR2 (Fibroblast growth factor receptor 2) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • NECTIN4 (Nectin Cell Adhesion Molecule 4) • NTRK (Neurotrophic receptor tyrosine kinase) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
|
HER-2 amplification • HER-2 expression • NECTIN4 expression
14d
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • NECTIN4 (Nectin Cell Adhesion Molecule 4) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
|
NECTIN4 expression
2ms
Production and characterization of single-chain variable fragment antibodies targeting the breast cancer tumor marker nectin-4. (PubMed, Front Immunol)
As results from ELISA indicated that L4 bound more efficiently to fixed nectin-4 ectodomain, molecular docking analysis was further performed and demonstrated that L4 possesses multiple polar contacts with nectin-4 and diversity in interacting residues. Overall, the nectin-4-specific scFvs could recognize nectin-4 expressed by breast cancer cells and have the merit of being further explored for potential diagnostic and therapeutic applications.
Journal
|
NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
NECTIN4 expression
3ms
Nectin-4 expression in a subset of cutaneous adnexal carcinomas: A potential target for therapy with enfortumab vedotin. (PubMed, J Cutan Pathol)
Increased Nectin-4 expression in a subset of cutaneous adnexal carcinomas, particularly sebaceous carcinomas, reveals that EV is a potential therapeutic option for these tumors.
Journal
|
NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
NECTIN4 expression
|
Padcev (enfortumab vedotin-ejfv)
3ms
Associations of TACSTD2/TROP2 and NECTIN-4/NECTIN-4 with molecular subtypes, PD-L1 expression, and FGFR3 mutational status in two advanced urothelial bladder cancer cohorts. (PubMed, Histopathology)
TACSTD2/TROP2 and NECTIN-4/NECTIN-4 are widely expressed in aUC, independent of FGFR3 alterations or PD-L1 expression, thus representing a suitable target for ADC treatment in the majority of aUC. The expression loss was associated with aggressive morphomolecular aUC subtypes, i.e. neuroendocrine(-like) and sarcomatoid aUC.
Journal • PD(L)-1 Biomarker • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1) • FGFR3 (Fibroblast growth factor receptor 3) • NECTIN4 (Nectin Cell Adhesion Molecule 4) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
|
PD-L1 expression • FGFR3 mutation • NECTIN4 expression • FGFR3 expression
|
Trodelvy (sacituzumab govitecan-hziy) • Padcev (enfortumab vedotin-ejfv)
3ms
An iodine‑labelled Antibody-drug conjugate PET probe for noninvasive monitoring of Nectin-4 expression in urothelial carcinoma. (PubMed, Int J Pharm)
I-EV was successfully prepared with high specificity and binding affinity of Nectin-4. This radioactive probe completely simulates the internal circulation of ADC drugs and tumour uptake and retention, which will greatly improve the clinical application of ADC therapy.
Journal
|
NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
NECTIN4 expression
|
Padcev (enfortumab vedotin-ejfv)
3ms
Trial completion date • Trial primary completion date • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • ALK (Anaplastic lymphoma kinase) • PGR (Progesterone receptor) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
EGFR mutation • ALK fusion • NECTIN4 expression
|
Keytruda (pembrolizumab) • BT8009
3ms
Estrogen receptor beta suppresses the androgen receptor oncogenic effects in triple-negative breast cancer. (PubMed, Chin Med J (Engl))
This study suggests that ERβ functions as a suppressor mediating the effect of AR in TNBC prognosis and cell proliferation. Therefore, our current research facilitates a better understanding of the role and mechanisms of AR in TNBC carcinogenesis.
Journal
|
ER (Estrogen receptor) • AR (Androgen receptor) • NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
ER positive • AR positive • NECTIN4 expression • AR negative
4ms
Occurrence of NECTIN4 amplification in solid tumors and enfortumab vedotin response in metastatic urothelial cancer. (ASCO-GU 2024)
Our study highlights the value of NECTIN4 amplifications to predict EV responses in patients with mUC. NECTIN4 amplifications occur frequently in different cancer types and therefore have the potential to be a novel tumor-agnostic genomic biomarker that enables tailored NECTIN4-targeted therapies in various entities.
BRCA Biomarker • Metastases
|
BRCA (Breast cancer early onset) • NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
NECTIN4 expression
|
Padcev (enfortumab vedotin-ejfv)
4ms
Comparison of tissue based FGFR mutation detection by Therascreen FGFR with UroTyper FGFR and ADC test and relevance for potential co-targeting with TROP2 and NECTIN4: Preview of Bladder BRIDGister. (ASCO-GU 2024)
Background: In view of the efficacy of FGFR targeting in early and advanced bladder cancer, as has been shown for erdafitinib in the THOR and NORSE trial, molecular testing of FGFR mutations and fusions will soon become clinical routine worldwide... PCR-based FGFR assessment by Therascreen and UroTyper is highly concordant and enables fast, local FGFR assessment within few hours. FGFR3 mutations are associated with increased TROP2 & NECTIN4 expression indicating potential synergistic options which warrants further exploration as part of molecularly stratified clinical trials.
FGFR3 (Fibroblast growth factor receptor 3) • FGFR (Fibroblast Growth Factor Receptor) • NECTIN4 (Nectin Cell Adhesion Molecule 4) • PPARG (Peroxisome Proliferator Activated Receptor Gamma) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
|
FGFR3 mutation • FGFR mutation • FGFR fusion • FGFR3 S249C • FGFR3 overexpression • FGFR3 Y373C • NECTIN4 expression • FGFR3 G370C • FGFR3 R248C • FGF3 overexpression
|
therascreen® FGFR RGQ RT-PCR Kit • Uromonitor®
|
Balversa (erdafitinib)
4ms
Sequencing of erdafitinib (erda) and enfortumab vedotin (EV) in patients (pts) with fibroblast growth factor receptor (FGFR2/3) altered (alt) advanced urothelial cancer (aUC): Analysis of UNITE database. (ASCO-GU 2024)
We showed longersurvival in pts with FGFR2/3 alt aUC who received both EV and E regardless of sequence, which may reflect guarantee-time bias. Additional limitations include retrospective nature, modest sample size, no central scan review, lack of data for pts who received E only, selection and confounding biases. Larger prospective studies are needed to determine optimal sequencing and putative biomarkers.
Clinical • Metastases
|
FGFR2 (Fibroblast growth factor receptor 2) • NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
NECTIN4 expression
|
Balversa (erdafitinib) • Padcev (enfortumab vedotin-ejfv)
4ms
Nectin-4 has emerged as a compelling target for breast cancer. (PubMed, Eur J Pharmacol)
The present review systematically describes the significance of Nectin-4 in each aspect of breast cancer, as well as the molecular mechanisms of these aspects mediated by Nectin-4. We further highlight ongoing or proposed therapeutic strategies for breast cancer specific to Nectin-4.
Review • Journal
|
NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
NECTIN4 expression
4ms
Expression of PVRL4, a molecular target for cancer treatment, is transcriptionally regulated by FOS. (PubMed, Oncol Rep)
Enfortumab vedotin, an antibody‑drug conjugate targeting PVRL4, is clinically used for the treatment of urothelial bladder cancer...Furthermore, RNA‑seq analysis using breast cancer cells treated with PVRL4 small interfering RNA revealed its possible involvement in the cytokine response and immune system. These data suggested that FOS was involved, at least partly, in the regulation of PVRL4 expression in breast cancer cells, and that elevated PVRL4 expression may regulate the response of cancer cells to cytokines and the immune system.
Journal
|
NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
NECTIN4 expression
|
Padcev (enfortumab vedotin-ejfv)
4ms
Expression of Nectin-4 in Chromophobe Renal Cell Carcinoma in a multicenter cohort - early prognostic and therapeutic considerations. (PubMed, Oncology)
In chRCC a small subset of tumors expresses Nectin-4 potentially amenable to Nectin-4 directed treatment. Expression of Nectin-4 is not associated with parameters of aggressiveness or survival. Due to the rare incidence of chRCC further studies with larger cohorts are warranted.
Journal
|
NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
NECTIN4 expression
|
Padcev (enfortumab vedotin-ejfv)
4ms
NECTIN-4 targeted theranostics for urothelial cancer: getting ready for primetime? (PubMed, Expert Rev Anticancer Ther)
Enfortumab vedotin (EV) gained Food and Drug Administration approval for advanced UC treatment, but patient selection based on NECTIN-4 expression remains challenging...In summary, the study from Duan and colleagues introduces a promising molecular imaging technique that could aid in patient selection for EV therapy and the development of targeted drugs for UC. It also highlights the potential of LAFOV PET/CT in enhancing imaging precision and expanding future therapeutic possibilities for UC.
Review • Journal
|
NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
NECTIN4 expression
|
Padcev (enfortumab vedotin-ejfv)
4ms
Prognostic Potential of Nectin Expressions in Colorectal Cancer: An Exploratory Study. (PubMed, Int J Mol Sci)
This study underscores the potential prognostic significance of nectins in CRC. The high prevalence of nectin-4-expressing cells offers promising avenues for further evaluation in targeted therapeutic interventions with already available agents such as PADCEV.
Retrospective data • Journal
|
CEACAM5 (CEA Cell Adhesion Molecule 5) • NECTIN4 (Nectin Cell Adhesion Molecule 4) • NECTIN2 (Nectin Cell Adhesion Molecule 2)
|
NECTIN4 expression
|
Padcev (enfortumab vedotin-ejfv)
4ms
Assessment of PD-L1, TROP2, and nectin-4 expression in penile squamous cell carcinoma. (PubMed, Hum Pathol)
High expression of TROP2 and nectin-4 in pSCC support evaluation of these markers as therapeutic targets pending validation of our findings.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • NECTIN4 (Nectin Cell Adhesion Molecule 4) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
|
PD-L1 expression • PD-L1 negative • TROP2 expression • TROP2 overexpression • NECTIN4 expression
|
PD-L1 IHC 22C3 pharmDx
5ms
Metastases
|
NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
NECTIN4 expression
5ms
Antibody-drug conjugates directed against NECTIN-4 as a new treatment option for patients with metastatic urothelial carcinoma (PubMed, Urologie)
This compact review article highlights the background and importance of nectins in cancer therapy, focusing specifically on the antibody-drug conjugate enfortumab vedotin (EV) as a targeted treatment option for metastatic urothelial carcinoma. The evolving understanding of nectin-4 expression and its impact on EV therapy underscores the need for personalized approaches to ensure optimal patient outcomes. Further investigation into biomarker-guided therapies and prospective clinical trials are critical to refining patient selection and treatment strategies.
Journal • Metastases
|
NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
NECTIN4 expression
|
Padcev (enfortumab vedotin-ejfv)
5ms
Enfortumab vedotin (EV): Correlation of estrogen receptor status and Nectin-4 expression with single agent efficacy in breast XPDX models (SABCS 2023)
We have characterized a panel of breast XPDX models based on Nectin-4 staining and in vivo sensitivity to EV and correlated activity with protein and receptor staining and known mutations. This data is a valuable tool in further developing EV and identifying its potential in treating breast cancer.
Clinical
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • CDK4 (Cyclin-dependent kinase 4) • NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
ER positive • HR positive • NECTIN4 expression
|
Padcev (enfortumab vedotin-ejfv)
5ms
Anti-tumor activity of a recombinant measles virus against canine lung cancer cells. (PubMed, Sci Rep)
To understand difference in efficacy among canine lung cancer cell lines, we compared virus growth and gene expression pattern after virus treatment in the three canine lung cancer cell lines; virus growth was highest in CLAC cells compared with the other cell lines and the induction of interferon (IFN)-beta and IFN-stimulated genes was at lower levels in CLAC cells. These results suggested that rMV-SLAMblind exhibits oncolytic effect against some canine lung cancer cells and the cellular response after the virus infection may influence its efficacy.
Journal
|
CXCL10 (Chemokine (C-X-C motif) ligand 10)
|
NECTIN4 expression
6ms
Expression of nectin-4 in prostate cancer. (PubMed, North Clin Istanb)
We found that nectin-4 was not expressed in prostate cancer tissues but was expressed in ASAP-and benign prostate gland containing tissues. We believe that prospective studies with more patients and samples including radical prostatectomy materials will reveal the relationship between nectin-4 and prostate cancer more clearly.
Journal
|
NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
NECTIN4 expression
7ms
Clinical
|
NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
NECTIN4 expression
7ms
Nectin-4 is frequently expressed in primary salivary gland cancer and corresponding lymph node metastases and represents an important treatment-related biomarker. (PubMed, Clin Exp Metastasis)
Enfortumab vedotin, an antibody-drug conjugate binding to Nectin-4, recently gained FDA approval for third-line urothelial carcinoma...There was a statistical tendency towards a more favorable disease-free survival among SaDu patients with a higher Nectin-4 expression (p = 0.09). Nectin-4 is expressed in SGC and therefore represents a potential therapeutic target, especially in entities with a high rate of local recurrence and metastatic spread such as SaDu and ACC.
Journal
|
NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
NECTIN4 expression
|
Padcev (enfortumab vedotin-ejfv)
7ms
Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy (clinicaltrials.gov)
P1, N=30, Recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2023 --> Sep 2024 | Trial primary completion date: Sep 2023 --> Sep 2024
Trial completion date • Trial primary completion date • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1) • FGFR2 (Fibroblast growth factor receptor 2) • NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
PD-L1 expression • NECTIN4 expression
|
Balversa (erdafitinib) • Padcev (enfortumab vedotin-ejfv)
8ms
Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for treatment of Nectin-4-expressing Cancers. (PubMed, Mol Cancer Ther)
Enfortumab vedotin (EV) is the first nectin-4-targeting antibody-drug conjugate (ADC) approved by the FDA for the treatment of urothelial cancer. Overall, 9MW2821 is a nectin-4-directed, investigational antibody-drug conjugate based on innovative technology that endowed the drug with compelling preclinical antitumor activity and a favorable therapeutic index. The 9MW2821 antibody-drug conjugate is being investigated in a Phase I/II clinical trial (NCT05216965) in patients with advanced solid tumors.
Preclinical • Journal
|
NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
NECTIN4 expression
|
Padcev (enfortumab vedotin-ejfv) • 9MW2821
8ms
KS-EMPD-1: a novel cell line of primary extramammary Paget's disease. (PubMed, Hum Cell)
KS-EMPD-1 was highly sensitive to docetaxel and paclitaxel on chemosensitivity test. The KS-EMPD-1 cell line is a promising resource for basic and preclinical research on EMPD to better define the tumor characteristics and treatment strategy of this rare cancer.
Preclinical • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
HER-2 expression • NECTIN4 expression
|
paclitaxel • docetaxel
8ms
Preliminary results from a phase I/II study of 9MW2821, an antibody-drug conjugate targeting nectin-4, in patients with advanced solid tumors (ESMO 2023)
Conclusions The results showed that 9MW2821 had manageable safety profile and promising antitumor activity. Enrollment continues to determine efficacy of 9MW2821 in certain solid tumors.
Clinical • P1/2 data • Metastases
|
NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
NECTIN4 expression
|
9MW2821
9ms
Nectin-4 as a Predictive Marker for Poor Prognosis of Endometrial Cancer with Mismatch Repair Impairment. (PubMed, Cancers (Basel))
Bioinformatics analysis revealed that alteration in Nectin-4 and MMR genes is associated with Nectin-4 expression in EC. To the best of our knowledge, this is the first study to show that Nectin-4 expression may be a potential biomarker for EC diagnosis and that high Nectin-4 expression in MMR-deficient patients with EC can predict short progression-free survival, thus providing clues to identify patients for adjuvant therapy.
Journal • Mismatch repair
|
MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
NECTIN4 expression • NECTIN4 underexpression
9ms
Metastatic Bladder Cancer Expression and Subcellular Localization of Nectin-4 and Trop-2 in Variant Histology: A Rapid Autopsy Study. (PubMed, Clin Genitourin Cancer)
UC and non-NE variants express notable level of Nectin-4 and Trop-2 in both primary and metastatic lesions. Membrane staining of Nectin-4 and Trop-2 is present but cytoplasmic staining is a more common event in both mUC and mUC variant histology. These findings support evaluation of EV and SG in heavily treated variant histology BC and urge attention on the clinical relevance of cytoplasmic localization of ADC targets.
Journal • Metastases
|
NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
NECTIN4 expression
|
Trodelvy (sacituzumab govitecan-hziy) • Padcev (enfortumab vedotin-ejfv)
11ms
First-in-human study of the radioligand 68Ga-N188 targeting nectin-4 for PET/CT imaging of advanced urothelial carcinoma. (PubMed, Clin Cancer Res)
A clear correlation between PET SUV value and nectin-4 expression was observed, supporting the application of 68Ga-N188 PET as a companion diagnostic tool for optimizing treatments that target nectin-4.
P1 data • Journal • Metastases
|
NECTIN4 expression
|
Padcev (enfortumab vedotin-ejfv)
11ms
Molecular characterization of nectin-4 in non-small cell lung cancer subtypes. (ASCO 2023)
As enfortumab vedotin, an antibody-drug conjugate directed against nectin-4, has been FDA approved for advanced urothelial carcinoma, this holds treatment implications...NFE2L2 alterations in SQ and STK11, KEAP1 mutations in AD, which are associated with poor immunotherapy (IO) response, were enriched in Q4 tumors. This suggests that the immune landscape associated with high nectin-4 expression in NSCLC may be driven by the dysregulated KEAP1-NFE2L2 pathway. Targeted therapy towards nectin-4 may benefit these NSCLC subtypes that do not respond well to IO.
PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • STK11 (Serine/threonine kinase 11) • CD8 (cluster of differentiation 8) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • IDO1 (Indoleamine 2,3-dioxygenase 1) • NECTIN4 (Nectin Cell Adhesion Molecule 4) • CD80 (CD80 Molecule) • CD86 (CD86 Molecule)
|
PD-L1 expression • HER-2 mutation • STK11 mutation • KEAP1 mutation • NFE2L2 mutation • NECTIN4 expression
|
PD-L1 IHC 22C3 pharmDx • MI Tumor Seek™
|
Padcev (enfortumab vedotin-ejfv)
12ms
Scratching the surface: NECTIN-4 as a Surrogate for Enfortumab Vedotin Resistance. (PubMed, Clin Cancer Res)
A recent article shows that NECTIN-4 membranous expression changes with progression to metastatic disease and that low NECTIN-4 expression is potentially associated with EV resistance. These data argue for incorporation of NECTIN-4 expression into future biomarker strategies.
Journal
|
NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
NECTIN4 expression • NECTIN4 underexpression
|
Padcev (enfortumab vedotin-ejfv)
12ms
A Specificity Protein 1 assists the progression of the papillary thyroid cell line by initiating NECTIN4. (PubMed, Endocr Metab Immune Disord Drug Targets)
In conclusion, our study, for the first time, demonstrated that SP1 could control the transcriptional regulation of NECTIN4 and accelerate the growth of PTC, which may provide a new potential therapeutic target for PTC patients.
Preclinical • Journal
|
NECTIN4 (Nectin Cell Adhesion Molecule 4) • SP1 (Sp1 Transcription Factor)
|
NECTIN4 expression
12ms
The prognostic significance of Nectin-2 and Nectin-4 expression in glial tumors. (PubMed, Pathol Res Pract)
These results suggest that Nectin-2 and Nectin-4 expression may be used as an independent prognostic indicator for patients with II/III gliomas. This study contributes to the development of personalized care for patients with glioma and provides a basis for further research on nectin-based immunotherapy for brain tumors.
Journal • IO biomarker
|
NECTIN4 (Nectin Cell Adhesion Molecule 4) • NECTIN2 (Nectin Cell Adhesion Molecule 2)
|
NECTIN4 expression
12ms
Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs' development. (PubMed, Br J Cancer)
In mCRC, expression levels of Trop-2 and Nectin-4 are heterogeneous, suggesting a target-driven development of anti-Trop2 and anti-Nectin-4 ADCs. Medium/high Trop-2 expression is associated with worse prognosis and higher benefit from chemotherapy intensification.
Journal • Metastases
|
NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
NECTIN4 expression
|
Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium
1year
Prognostic value of nectin-4 in human cancers: A meta-analysis. (PubMed, Front Oncol)
We also found that high nectin-4 expression was associated with tumor diameter (big vs small) (OR: 1.96, 95% CI: 1.02-3.75), tumor stage (III-IV vs I-II) (OR: 2.04, 95% CI: 1.01-4.12) and invasion depth (T3+T4 vs T2+T1) (OR: 3.95, 95% CI: 2.06-7.57). Nectin-4 can be used as an effective prognostic indicator for specific cancers.
Retrospective data • Review
|
NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
NECTIN4 expression
1year
Phase 1/2 study of the safety, pharmacokinetics, and preliminary clinical activity of BT7480 in patients with nectin-4 associated advanced malignancies (AACR 2023)
PK and PD analyses will be performed to support dose escalation decisions and to further the understanding of safety and clinical activity signals as a result of treatment with BT7480. This study is actively recruiting.
Clinical • P1/2 data • PK/PD data • IO biomarker • Metastases
|
NECTIN4 (Nectin Cell Adhesion Molecule 4) • TNFRSF9 (TNF Receptor Superfamily Member 9)
|
NECTIN4 expression
|
BT7480